GlaxoSmithKline Pharmaceuticals Limited (GLAXO) - Net Assets

Latest as of September 2025: Rs17.08 Billion INR ≈ $184.68 Million USD

Based on the latest financial reports, GlaxoSmithKline Pharmaceuticals Limited (GLAXO) has net assets worth Rs17.08 Billion INR (≈ $184.68 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs36.65 Billion ≈ $396.37 Million USD) and total liabilities (Rs19.57 Billion ≈ $211.69 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check GLAXO cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	Rs17.08 Billion
% of Total Assets	46.59%
Annual Growth Rate	3.81%
5-Year Change	30.17%
10-Year Change	15.05%
Growth Volatility	22.72

GlaxoSmithKline Pharmaceuticals Limited - Net Assets Trend (2005–2025)

This chart illustrates how GlaxoSmithKline Pharmaceuticals Limited's net assets have evolved over time, based on quarterly financial data. Also explore GLAXO total assets for the complete picture of this company's asset base.

Annual Net Assets for GlaxoSmithKline Pharmaceuticals Limited (2005–2025)

The table below shows the annual net assets of GlaxoSmithKline Pharmaceuticals Limited from 2005 to 2025. For live valuation and market cap data, see GLAXO stock market capitalisation.

Year	Net Assets	Change
2025-03-31	Rs19.51 Billion ≈ $211.03 Million	+9.77%
2024-03-31	Rs17.78 Billion ≈ $192.24 Million	+2.09%
2023-03-31	Rs17.41 Billion ≈ $188.31 Million	-34.61%
2022-03-31	Rs26.63 Billion ≈ $287.99 Million	+77.64%
2021-03-31	Rs14.99 Billion ≈ $162.12 Million	-17.66%
2020-03-31	Rs18.21 Billion ≈ $196.89 Million	-14.92%
2019-03-31	Rs21.40 Billion ≈ $231.41 Million	+4.01%
2018-03-31	Rs20.57 Billion ≈ $222.49 Million	+2.52%
2017-03-31	Rs20.07 Billion ≈ $217.03 Million	+18.32%
2016-03-31	Rs16.96 Billion ≈ $183.42 Million	-30.60%
2015-03-31	Rs24.44 Billion ≈ $264.32 Million	+22.83%
2014-03-31	Rs19.90 Billion ≈ $215.18 Million	-0.85%
2013-03-31	Rs20.07 Billion ≈ $217.03 Million	+3.67%
2012-03-31	Rs19.36 Billion ≈ $209.34 Million	-0.81%
2011-03-31	Rs19.52 Billion ≈ $211.06 Million	+9.27%
2010-03-31	Rs17.86 Billion ≈ $193.16 Million	+13.36%
2009-03-31	Rs15.76 Billion ≈ $170.39 Million	+14.10%
2008-03-31	Rs13.81 Billion ≈ $149.33 Million	+14.62%
2007-03-31	Rs12.05 Billion ≈ $130.29 Million	+26.40%
2006-03-31	Rs9.53 Billion ≈ $103.08 Million	+3.18%
2005-03-31	Rs9.24 Billion ≈ $99.90 Million	--

Equity Component Analysis

This analysis shows how different components contribute to GlaxoSmithKline Pharmaceuticals Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 1058631600000.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (March 2025)

Component	Amount	Percentage
Retained Earnings	Rs10.59 Billion	54.25%
Common Stock	Rs1.69 Billion	8.68%
Other Comprehensive Income	Rs7.23 Billion	37.07%
Total Equity	Rs19.51 Billion	100.00%

GlaxoSmithKline Pharmaceuticals Limited Competitors by Market Cap

The table below lists competitors of GlaxoSmithKline Pharmaceuticals Limited ranked by their market capitalization.

Company	Market Cap
NorthWestern Corporation NASDAQ:NWE	$4.28 Billion
Mueller Water Products NYSE:MWA	$4.28 Billion
Shenzhen H&T Intelligent Control Co Ltd SHE:002402	$4.28 Billion
Shenzhen O-Film Tech Co Ltd SHE:002456	$4.28 Billion
Gujarat Fluorochemicals Limited NSE:FLUOROCHEM	$4.28 Billion
Challenger Ltd AU:CGF	$4.28 Billion
E-L Financial Corp Ltd TO:ELF	$4.28 Billion
ENSTAR GROUP LTD DL-01 F:48R	$4.27 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in GlaxoSmithKline Pharmaceuticals Limited's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 17,776,397,000 to 19,513,100,000, a change of 1,736,703,000 (9.8%).
Net income of 9,275,829,000 contributed positively to equity growth.
Dividend payments of 7,493,800,000 reduced retained earnings.
Other comprehensive income decreased equity by 85,254,000.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	Rs9.28 Billion	+47.54%
Dividends Paid	Rs7.49 Billion	-38.4%
Other Comprehensive Income	Rs-85.25 Million	-0.44%
Other Changes	Rs39.93 Million	+0.2%
Total Change	Rs-	9.77%

Book Value vs Market Value Analysis

This analysis compares GlaxoSmithKline Pharmaceuticals Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 20.28x
The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
The price-to-book ratio has decreased from 44.17x to 20.28x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2005-03-31	Rs52.89	Rs2336.40	x
2006-03-31	Rs55.54	Rs2336.40	x
2007-03-31	Rs71.12	Rs2336.40	x
2008-03-31	Rs81.51	Rs2336.40	x
2009-03-31	Rs93.00	Rs2336.40	x
2010-03-31	Rs105.43	Rs2336.40	x
2011-03-31	Rs115.20	Rs2336.40	x
2012-03-31	Rs114.26	Rs2336.40	x
2013-03-31	Rs118.46	Rs2336.40	x
2014-03-31	Rs117.45	Rs2336.40	x
2015-03-31	Rs144.27	Rs2336.40	x
2016-03-31	Rs100.12	Rs2336.40	x
2017-03-31	Rs118.46	Rs2336.40	x
2018-03-31	Rs121.44	Rs2336.40	x
2019-03-31	Rs126.31	Rs2336.40	x
2020-03-31	Rs107.47	Rs2336.40	x
2021-03-31	Rs87.26	Rs2336.40	x
2022-03-31	Rs157.19	Rs2336.40	x
2023-03-31	Rs102.79	Rs2336.40	x
2024-03-31	Rs104.93	Rs2336.40	x
2025-03-31	Rs115.19	Rs2336.40	x

Capital Efficiency Dashboard

This dashboard shows how efficiently GlaxoSmithKline Pharmaceuticals Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 47.54%
The company demonstrates strong efficiency in generating profits from shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 24.74%
• Asset Turnover: 0.91x
• Equity Multiplier: 2.11x
Recent ROE (47.54%) is above the historical average (30.49%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2005	36.56%	23.95%	1.00x	1.53x	Rs2.45 Billion
2006	53.21%	33.40%	1.00x	1.59x	Rs4.12 Billion
2007	45.74%	34.83%	0.88x	1.49x	Rs4.31 Billion
2008	39.65%	34.05%	0.79x	1.47x	Rs4.09 Billion
2009	37.52%	34.91%	0.73x	1.47x	Rs4.34 Billion
2010	28.43%	26.62%	0.76x	1.40x	Rs3.29 Billion
2011	28.72%	26.06%	0.77x	1.44x	Rs3.65 Billion
2012	22.14%	18.02%	0.78x	1.58x	Rs2.35 Billion
2013	28.00%	21.17%	0.86x	1.54x	Rs3.61 Billion
2014	19.15%	14.45%	0.84x	1.57x	Rs1.82 Billion
2015	15.59%	14.45%	0.82x	1.32x	Rs1.37 Billion
2016	22.18%	13.25%	0.93x	1.80x	Rs2.07 Billion
2017	16.78%	11.58%	0.97x	1.50x	Rs1.36 Billion
2018	17.05%	12.21%	0.73x	1.92x	Rs1.45 Billion
2019	20.81%	14.24%	0.80x	1.83x	Rs2.31 Billion
2020	5.12%	2.89%	1.03x	1.72x	Rs-888.56 Million
2021	24.23%	12.24%	0.94x	2.11x	Rs2.10 Billion
2022	63.64%	51.70%	0.71x	1.74x	Rs14.28 Billion
2023	35.07%	18.78%	0.98x	1.91x	Rs4.37 Billion
2024	33.19%	17.08%	0.97x	2.00x	Rs4.12 Billion
2025	47.54%	24.74%	0.91x	2.11x	Rs7.32 Billion

Industry Comparison

This section compares GlaxoSmithKline Pharmaceuticals Limited's net assets metrics with peer companies in the Drug Manufacturers - General industry.

Industry Context

Industry: Drug Manufacturers - General
Average net assets among peers: $9,348,280,848
Average return on equity (ROE) among peers: 24.18%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
GlaxoSmithKline Pharmaceuticals Limited (GLAXO)	Rs17.08 Billion	36.56%	1.15x	$4.28 Billion
NGL Fine-Chem Limited (NGLFINE)	$328.16 Million	25.38%	1.03x	$147.96 Million
Pfizer Limited (PFIZER)	$42.17 Billion	18.20%	0.16x	$2.33 Billion
Sanofi India Limited (SANOFI)	$10.14 Billion	15.29%	0.39x	$848.62 Million
SANOFI CONS HEALTHC IND L (SANOFICONR)	$2.73 Billion	66.30%	0.58x	$1.19 Billion
SENORES PHARMACEUTICALS L (SENORES)	$94.96 Million	7.21%	0.53x	$447.85 Million
TTK Healthcare Limited (TTKHLTCARE)	$620.96 Million	12.68%	1.22x	$138.16 Million

About GlaxoSmithKline Pharmaceuticals Limited

NSE:GLAXO India Drug Manufacturers - General

Market Cap

$4.28 Billion

Rs395.80 Billion INR

Market Cap Rank

#3979 Global

#169 in India

Share Price

Rs2336.40

Change (1 day)

-1.28%

52-Week Range

Rs2259.50 - Rs3466.20

All Time High

Rs3466.20